サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：乳がん治療薬市場- 世界の産業規模、シェア、動向、機会、予測、2017-2027年セグメント：治療法別、（化学療法薬別、ホルモン療法別、標的療法別、エンドユーザー別、地域別
市場調査レポート
商品コード
1228257

乳がん治療薬市場- 世界の産業規模、シェア、動向、機会、予測、2017-2027年セグメント：治療法別、（化学療法薬別、ホルモン療法別、標的療法別、エンドユーザー別、地域別

Breast Cancer Therapeutics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2017-2027 Segmented By Therapy, By (Chemotherapy Drugs, By Hormone Therapy, By Targeted Therapy, By End User, and By Region
出版日: | 発行: TechSci Research | ページ情報: 英文 116 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

乳がん治療薬市場- 世界の産業規模、シェア、動向、機会、予測、2017-2027年セグメント：治療法別、（化学療法薬別、ホルモン療法別、標的療法別、エンドユーザー別、地域別
出版日: 2023年03月01日
発行: TechSci Research
ページ情報: 英文 116 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

乳がん治療薬の世界市場は、予測期間である2023年から2027年にかけて目覚ましいCAGRで成長すると予測されています。

がんなどの慢性疾患にかかりやすい老年人口が増加していることが、乳がん治療薬の世界市場の成長を促進しています。

乳がん症例の増加が市場成長を後押し

世界中で乳がんの有病率が高まっており、多くの患者に対する効果的な治療に対する需要が高まっていることから、乳がん治療薬市場の成長が促進されると予想されます。乳がんは、世界中で流行しているがんの1つと考えられており、診断ソリューションの強化が市場成長を促進すると期待されています。予防医療や早期治療に対する需要の高まりは、その多くの利点から、個人が診断手続きに行くようになり、乳がん治療薬の世界市場の成長をさらに後押ししています。

政府別啓発プログラムの開始が市場成長を促進

政府機関による乳がん検診の取り組みや、公的機関が導入する支援プログラムは、世界の乳がん治療薬市場の成長を刺激すると予想されています。WHOの報告書によると、乳がんの早期発見は、乳がん死亡率の最小化に役立ち、乳がん患者の生存率を加速させるとのことです。世界中の数多くの政府機関が、特に50歳以上の女性を中心に、乳がん検診を受けるよう促しています。こうした検診の取り組みや啓発プログラムは、乳がんの効果的な治療のための薬剤の利用を促進し、予測期間中の世界の乳がん治療薬市場の成長を促すと予測されます。

標的治療に対する需要の高まりが市場成長を後押し

乳がんの治療は、世界中の腫瘍学者にとって困難な課題です。治療法の有無や選択肢は、患者さんによって異なります。標的療法は、周囲の健康な細胞を傷つけずに乳がん細胞を正確に狙い撃ちするため、他のどの治療法よりも好まれます。標的療法は、従来の治療法がもたらす数々の限界を克服するために、医療専門家を支援するものです。また、標的療法は、腫瘍医が事後対応的な治療よりも予防的な治療に重点を置くことを支援します。この治療法は、乳がんの進行期と診断された患者の治療効率を高め、乳がん治療薬の世界市場の成長にさらに貢献します。

利用可能なカスタマイズ

TechSci Researchでは、所定の市場データをもとに、企業固有のニーズに応じたカスタマイズを提供しています。本レポートでは、以下のカスタマイズが可能です。

企業情報

  • 追加的な市場企業の詳細分析とプロファイリング（最大5社）。

目次

第1章 製品セラピーの概要

第2章 調査手法

第3章 COVID-19が世界の乳がん治療薬市場に与える影響

第4章 顧客の声

第5章 エグゼクティブサマリー

第6章 乳がん治療薬の世界市場展望

  • 市場規模および予測
    • 金額別
  • 市場シェアと予測
    • 治療法別（化学療法、ホルモン療法、免疫療法、標的療法、その他）
    • エンドユーザー別（病院、専門クリニック、外来手術センター、その他）
    • 企業別（2021年）
    • 地域別
  • 製品市場マップ

第7章 北米の乳がん治療薬市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 治療法別（化学療法、ホルモン療法、免疫療法、標的療法、その他）
    • エンドユーザー別（病院、専門クリニック、外来手術センター、その他）
    • 国別
  • 北米国別分析
    • 米国
    • メキシコ
    • カナダ

第8章 欧州の乳がん治療薬市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 治療法別（化学療法、ホルモン療法、免疫療法、標的療法、その他）
    • エンドユーザー別（病院、専門クリニック、外来手術センター、その他）
    • 国別
  • 欧州国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第9章 アジア太平洋地域の乳がん治療薬市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 治療法別（化学療法、ホルモン療法、免疫療法、標的療法、その他）
    • エンドユーザー別（病院、専門クリニック、外来手術センター、その他）
    • 国別
  • アジア太平洋地域国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第10章 南米の乳がん治療薬市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 治療法別（化学療法、ホルモン療法、免疫療法、標的療法、その他）
    • エンドユーザー別（病院、専門クリニック、外来手術センター、その他）
    • 国別
  • 南米国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第11章 中東・アフリカの乳がん治療薬市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 治療法別（化学療法、ホルモン療法、免疫療法、標的療法、その他）
    • エンドユーザー別（病院、専門クリニック、外来手術センター、その他）
    • 国別
  • MEA：国別分析
    • 南アフリカの乳がん治療薬
    • サウジアラビアの乳がん治療薬
    • UAEの乳がん治療薬

第12章 市場力学

  • 促進要因
  • 課題

第13章 市場動向と新興国開拓

第14章 競合情勢

  • Novartis AG
  • Pfizer Inc.
  • Eli Lilly & Company
  • Merck Co. & Inc.
  • GlaxoSmithKline, Plc.
  • AstraZeneca Plc.
  • Bristol-Myers Squibb Company
  • Halozyme Inc.
  • Eisai Co., Ltd.
  • Fresenius Kabi AG

第15章 戦略的提言

目次
Product Code: 10617

The global breast cancer therapeutics market is expected to grow at an impressive CAGR in the forecast period, 2023-2027. The growing geriatric population who are more susceptible to several chronic illnesses such as cancer is propelling the growth of the global breast cancer therapeutics market.

The rising incidences and high prevalence rate of breast cancer across the world are expected to augment the global breast cancer therapeutics market. With this, extensive investment in research and development activities and technological advancements in cancer biology and pharmacology promote breast cancer therapeutics. Continuous upgrades help increase understanding of breast cancer at the molecular level, and the introduction of novel solutions has assisted in lowering the breast cancer mortality rate over the past few years. Newly developed therapeutics efficiently slow down the growth and proliferation of cancerous cells, which is projected to boost the global breast cancer therapeutics market in the upcoming years.

Rise in Cases of Breast Cancer Augments the Market Growth

The growing prevalence of breast cancer across the globe and the escalating demand for effective treatment for a large number of patients are expected to stimulate the growth of the breast cancer therapeutics market. Breast cancer is considered one of the prevalent forms of cancer across the world, and enhanced diagnostic solutions are expected to propel market growth. The escalating demand for preventive care and early treatment due to its numerous benefits led individuals to go for diagnostic procedures, further driving the global breast cancer therapeutics market growth.

Launch of Awareness Programs by Government Stimulates the Market Growth

The breast cancer screening initiatives by government bodies and supportive programs introduced by public organizations are anticipated to stimulate the growth of the global breast cancer therapeutics market. According to the WHO report, early detection of breast cancer assists in minimizing the breast cancer mortality rate and accelerates the survival rate among patients who have breast cancer. Numerous government bodies across the globe encourage people to undergo breast cancer screening, especially women aged 50 and over. The screening initiatives and awareness programs are projected to propel the utilization of drugs for the effective treatment of breast cancer, driving the global breast cancer therapeutics market growth over the forecast period.

Escalating Demand for Targeted Therapy Supports the Market Growth

Treatment for breast cancer across the globe is a challenging task for any medical oncologist. The availability of treatment and choice varies from patient to patient. Targeted therapy is preferred over any other therapy as it precisely targets the breast cancer cells without damaging the surrounding healthy cells. The targeted therapy aids medical professionals in overcoming numerous limitations posed by traditional treatments. Targeted therapy also helps oncologists focus more on preventive care than reactive care. This therapy enhances the treatment efficiency in patients diagnosed with advanced stages of breast cancer, which further contributes to the growth of the global breast cancer therapeutics market.

Market Segmentation

The global breast cancer therapeutics market is segmented into type, end users, and regional distribution. Based on the type, the market is divided into chemotherapy, hormone therapy, immunotherapies, targeted therapy, and others. The chemotherapy drugs are further divided into anthracyclines, taxanes, and antimetabolites, and hormone therapy is divided into selective estrogen receptor modulators, aromatase inhibitors, and others. Also, the targeted therapy is divided into monoclonal antibodies, a tyrosine kinase inhibitor, Herceptin, and others. Based on the end users, the market is divided into hospitals, specialty clinics, ambulatory surgical centers, and others. The market analysis also studies the regional segmentation, divided among the North American region, Asia-Pacific region, European region, South American region, and Middle East & African region.

Market Players

Novartis AG, Pfizer Inc., Eli Lilly & Company, Merck Co. & Inc., GlaxoSmithKline, Plc., AstraZeneca Plc., Bristol-Myers Squibb Company, Halozyme Inc., Eisai Co., Ltd., Fresenius Kabi AG are the leading market players contributing the growth of the global breast cancer therapeutics market.

Report Scope

In this report, global breast cancer therapeutics market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Breast Cancer Diagnostics Market, By Therapy:

  • Chemotherapy
    • Anthracyclines
    • Taxanes
    • Antimetabolites
    • Others
  • Hormone Therapy
    • Selective Estrogen Receptor Modulators
    • Aromatase Inhibitors
    • Others
  • Immunotherapies
  • Targeted Therapy
    • Monoclonal Antibodies
    • Tyrosine Kinase Inhibitor
    • Herceptin
    • Others
  • Others

Breast Cancer Diagnostics Market, By End-User:

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Others

Breast Cancer Diagnostics, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global breast cancer therapeutics market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Therapy Overview

2. Research Methodology

3. Impact of COVID-19 on Global Breast Cancer Therapeutics Market

4. Voice of Customer

5. Executive Summary

6. Global Breast Cancer Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)
      • 6.2.1.1. Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others)
      • 6.2.1.2. Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)
      • 6.2.1.3. Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)
    • 6.2.2. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
    • 6.2.3. By Company (2021)
    • 6.2.4. By Region
  • 6.3. Product Market Map

7. North America Breast Cancer Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)
      • 7.2.1.1. Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others)
      • 7.2.1.2. Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)
      • 7.2.1.3. Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)
    • 7.2.2. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
    • 7.2.3. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Breast Cancer Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapy
        • 7.3.1.2.2. By End User
    • 7.3.2. Mexico Breast Cancer Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapy
        • 7.3.2.2.2. By End User
    • 7.3.3. Canada Breast Cancer Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapy
        • 7.3.3.2.2. By End User

8. Europe Breast Cancer Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)
      • 8.2.1.1. Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others)
      • 8.2.1.2. Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)
      • 8.2.1.3. Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)
    • 8.2.2. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
    • 8.2.3. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Breast Cancer Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapy
        • 8.3.1.2.2. By End User
    • 8.3.2. Germany Breast Cancer Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapy
        • 8.3.2.2.2. By End User
    • 8.3.3. United Kingdom Breast Cancer Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapy
        • 8.3.3.2.2. By End User
    • 8.3.4. Italy Breast Cancer Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapy
        • 8.3.4.2.2. By End User
    • 8.3.5. Spain Breast Cancer Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapy
        • 8.3.5.2.2. By End User

9. Asia-Pacific Breast Cancer Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)
      • 9.2.1.1. Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others)
      • 9.2.1.2. Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)
      • 9.2.1.3. Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)
    • 9.2.2. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
    • 9.2.3. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Breast Cancer Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapy
        • 9.3.1.2.2. By End User
    • 9.3.2. India Breast Cancer Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapy
        • 9.3.2.2.2. By End User
    • 9.3.3. Japan Breast Cancer Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapy
        • 9.3.3.2.2. By End User
    • 9.3.4. South Korea Breast Cancer Therapeutics Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Therapy
        • 9.3.4.2.2. By End User
    • 9.3.5. Australia Breast Cancer Therapeutics Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Therapy
        • 9.3.5.2.2. By End User

10. South America Breast Cancer Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)
      • 10.2.1.1. Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others)
      • 10.2.1.2. Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)
      • 10.2.1.3. Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)
    • 10.2.2. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Breast Cancer Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapy
        • 10.3.1.2.2. By End User
    • 10.3.2. Argentina Breast Cancer Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapy
        • 10.3.2.2.2. By End User
    • 10.3.3. Colombia Breast Cancer Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapy
        • 10.3.3.2.2. By End User

11. Middle East and Africa Breast Cancer Therapeutics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)
      • 11.2.1.1. Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others)
      • 11.2.1.2. Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)
      • 11.2.1.3. Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)
    • 11.2.2. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
    • 11.2.3. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Breast Cancer Therapeutics Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Therapy
        • 11.3.1.2.2. By End User
    • 11.3.2. Saudi Arabia Breast Cancer Therapeutics Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Therapy
        • 11.3.2.2.2. By End User
    • 11.3.3. UAE Breast Cancer Therapeutics Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Therapy
        • 11.3.3.2.2. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Novartis AG
  • 14.2. Pfizer Inc.
  • 14.3. Eli Lilly & Company
  • 14.4. Merck Co. & Inc.
  • 14.5. GlaxoSmithKline, Plc.
  • 14.6. AstraZeneca Plc.
  • 14.7. Bristol-Myers Squibb Company
  • 14.8. Halozyme Inc.
  • 14.9. Eisai Co., Ltd.
  • 14.10. Fresenius Kabi AG

15. Strategic Recommendations